Kymera Therapeutics
KYMR
75 hedge funds and large institutions have $1.25B invested in Kymera Therapeutics in 2020 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 13 increasing their positions, 13 reducing their positions, and 16 closing their positions.
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
144% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 16
130% more capital invested
Capital invested by funds: $543M → $1.25B (+$705M)
44% more funds holding
Funds holding: 52 → 75 (+23)
7.79% more ownership
Funds ownership: 37.87% → 45.66% (+7.8%)
0% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$31.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.81M |
| 3 |
State Street
Boston,
Massachusetts
|
+$7.83M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.66M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$7.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$12.2M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$9.27M |
| 3 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$8.08M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$7.32M |
| 5 |
Goldman Sachs
New York
|
-$5.84M |
KYMR Hedge Fund Activity: Q4 2020 in Review
75 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Kymera Therapeutics (KYMR) for Q4 2020, worth a combined $1.25B — up 130% from $543M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new KYMR positions and 16 closed out — a net gain of 23 holders — while 13 added to existing stakes and 13 trimmed.
The largest buyer was BlackRock, adding an estimated $31.7M. The largest seller was Bain Capital Life Sciences Investors, cutting an estimated $12.2M.
- 75 institutional investors held Kymera Therapeutics (KYMR) as of Q4 2020, up from 52 in Q3 2020.
- Funds reported $1.25B of Kymera Therapeutics stock for Q4 2020, up 130% quarter-over-quarter.
- 39 funds opened new Kymera Therapeutics positions in Q4 2020 and 16 closed out, a net change of +23 holders.
- The largest Kymera Therapeutics buyer in Q4 2020 was BlackRock, an estimated $31.7M added.
- The largest Kymera Therapeutics seller in Q4 2020 was Bain Capital Life Sciences Investors, an estimated $12.2M sold.
Based on aggregated 13F filings for Q4 2020.